Semaglutide (Sema) Research Peptide

What is Semaglutide?

Semaglutide, usually shortened to Sema on a lab label, is a synthetic 31-amino-acid peptide developed by Novo Nordisk as a long-acting analogue of human glucagon-like peptide-1. Its class is the GLP-1 receptor agonist, and it engages that one receptor only. The sequence is native GLP-1 with three deliberate edits: a non-natural aminoisobutyric acid residue near the N-terminus that blocks cleavage by the enzyme DPP-4, an arginine swapped in for a lysine so there’s only one attachment point, and a fatty diacid joined to the remaining lysine through a spacer so the peptide binds albumin and stays in circulation for days. Lau and colleagues described the design work in 2015. The CAS number is 910463-68-2.

Researchers order it because it’s the cleanest tool for a GLP-1 receptor question. Everything downstream of that receptor, from cAMP in a cell line to feeding behavior in a rodent, can be studied without a second receptor confounding the result. We stock it in 10mg lyophilized vials on the semaglutide product page, vialed, finished, tested and shipped in the USA.

Structure and mechanism

At 31 residues it’s shorter than tirzepatide and retatrutide, which are 39 each, and it’s the only one of the three built directly on the native GLP-1 sequence. The GLP-1 receptor is a class B G-protein-coupled receptor. When semaglutide binds it, the receptor couples mainly through Gs to raise cAMP, and the standard readout in a transfected cell line is cAMP accumulation, with native GLP-1 as the natural comparator. Beta-arrestin recruitment and internalization follow, and how those compare with the native ligand is a live topic in the signaling-bias literature.

The fatty diacid side chain is the reason the molecule behaves differently from native GLP-1 in vivo. Native GLP-1 is cleared within minutes; the albumin-bound analogue persists for days. Tirzepatide and retatrutide both borrow that strategy. In rodent models GLP-1 receptor activation is associated with reduced feeding, slowed gastric emptying and glucose-dependent insulin release from pancreatic beta cells, and receptor knockout and central versus peripheral studies have mapped where those effects originate. Most of that work was done with semaglutide, which is why it’s the baseline for the comparison at semaglutide vs tirzepatide vs retatrutide.

What the published research covers

The preclinical literature is broad. The 2015 discovery paper covers the medicinal chemistry, receptor potency and pharmacokinetics across species. Since then academic groups have used semaglutide in rodent models of obesity, diabetes, liver fat, atherosclerosis, kidney disease and neurodegeneration, and in brain-region studies mapping which GLP-1 receptor neurons drive the feeding effects. It’s also the usual comparator arm when a newer incretin analogue is characterized.

The clinical literature is the largest of any peptide in this class. Novo Nordisk’s SUSTAIN program in type 2 diabetes produced the cardiovascular outcomes trial reported by Marso and colleagues in 2016, and the STEP program in obesity produced the STEP 1 trial reported by Wilding and colleagues in 2021, both in the New England Journal of Medicine. Those trials reported lower HbA1c and body weight over their study periods and recorded the gastrointestinal adverse events common to the class, and later trials extended into cardiovascular and kidney outcomes. We list the landmarks so you know where the field stands; none of it describes a result to expect from a research vial.

Reconstitution and handling

The vial holds a lyophilized cake, white to off-white, under a rubber stopper and crimp seal. Let it reach room temperature before you open it so condensation doesn’t form on cold glass, then swab the stopper with alcohol and let it dry. The diluent we recommend for general lab work is bacteriostatic water, added slowly down the inside wall of the vial so the cake wets from the edge inward.

Swirl gently or let it stand for a few minutes; never shake it. Semaglutide’s fatty diacid side chain makes it prone to foaming and aggregation when agitated, and aggregates won’t go back into solution. You want a clear, colorless solution; if it stays cloudy after standing, set that vial aside and send us the lot number. Keep the process sterile, use a fresh sterile needle and syringe for each transfer, and label the vial with the compound, the concentration you made, the date and your initials before it goes into the fridge. How much diluent you add is a decision for your protocol.

Storage and stability

Keep the sealed lyophilized vial at -20C, protected from light, in its box or a foil pouch. Dry semaglutide is stable for a long time under those conditions, so keep stock frozen and reconstitute only what you’ll work through soon. A few days at ambient temperature in transit doesn’t harm lyophilized material, but it should go into the freezer when it arrives.

Once reconstituted, hold the solution at 2-8C, protected from light, and plan to use it within 28 days. Bacteriostatic water keeps microbial growth in check for that window, but the peptide is slowly hydrolyzing and adsorbing to the glass the whole time, so a solution at the end of that window isn’t equivalent to a fresh one. Avoid repeated freezing and thawing of the reconstituted solution, since each pass risks aggregation. If one vial has to cover several weeks of experiments, aliquot it into sterile vials right after reconstitution and keep those cold.

How it’s tested

Every semaglutide lot goes through the same routine as everything else we sell: HPLC purity, mass spectrometry identity and bacterial endotoxin, by a named third-party lab, with the lot COA on the product page. Purity on our lots is >99% by HPLC. A supplier’s word about its own material isn’t worth much, so the lab is named on the certificate where you can check it, and every certificate we’ve received is collected in the library at /coas/, searchable by compound and lot number.

Reading a certificate, match the lot number to your vial label first. Then find the HPLC section and look at the main peak area as a percentage of total, which is where the >99% figure comes from, and at the chromatogram to see how clean the baseline is. The mass spectrometry section should report an observed mass that agrees with the expected mass for the 31-residue lipidated sequence; that’s the identity check. The endotoxin result should sit below the lab’s stated limit.